Journal: eLife

Article Title: Multi-targeted therapy resistance via drug-induced secretome fucosylation

doi: 10.7554/eLife.75191

Figure Lengend Snippet: ( A ) Tracking of both fluorescently-tagged cells in 2D cell admixtures prepared as in , treated with or without indicated drugs [gefitinib (1 µM in H292, 0.08 µM in HCC827), erlotinib (0.1 µM in PC9, 1 µM in H358), osimertinib (0.08 µM in H1975, 0.01 µM in HCC4006, 0.08 µM in HCC827), dasatinib (0.8 µM in H2009), PHA665752 (0.6 µM in H1993), crizotinib (0.08 µM in EBC-1, 0.5 µM in H3122, 1 µM in HCC78), vemurafenib (0.1 µM in A375), dabrafenib (0.03 µM in A375), lapatinib (0.4 µM in SKBR3)], and incubated with or without 10 µg/mL recombinant PNGase F for indicated times. Values are relative to day 0 (means ± SD of three biological replicates). *p<0.05, **p<0.01, ***p<0.001, two-tailed Mann–Whitney U test. NS, not significant. ( B and C ) Cell cycle states of adherent cells and apoptosis of floating cells in indicated cell admixtures with same conditions as in A at indicated times. Representative of two independent experiments. ( D ) Proliferation of indicated DR clones upon (1) conditioned media CM co-culture or (2) fresh media control. Test DR clones were incubated with modified CM or fresh media as indicated, with or without 10 µg/mL recombinant PNGase F for indicated times. Maintaining drug concentrations are shown in . Values are relative to time point 0 (means ± SD of three biological replicates). For statistical analysis, Student’s t -test was used. NS, not significant. ( E ) Similar tracking experiments as in A, except upon FUT8 or SLC35C1 RNAi in sensitive cells for 48 hr prior to admixing and culture for 5 days. Cell admixtures treated with or without indicated drugs as in A and were incubated with or without 10 µg/mL recombinant PNGase F for indicated times. Values are relative to day 0 (means ± SD of two biological replicates). For statistical analysis, two-tailed Mann–Whitney U test was used. NS, not significant.

Article Snippet: PC9 and HCC827 [originally provided by J. K. Rho (Asan Medical Center, University of Ulsan, Seoul, Korea)], EBC-1 [Japanese Collection of Research Bioresources (JCRB) Cell Bank no. JCRB0820], HCC78 [German Collection of Microorganisms and Cell Cultures (DSMZ) GmbH no. ACC563], H3122 [originally provided by P. A. Jänne (Dana-Farber Cancer Institute, Boston, MA, USA)], and SKBR3 [originally provided by D. M. Helfman (KAIST, Daejeon, Korea)], all obtained in 2017, cell lines were grown in RPMI 1640 with the same supplementation as mentioned above.

Techniques: Incubation, Recombinant, Two Tailed Test, MANN-WHITNEY, Clone Assay, Co-Culture Assay, Control, Modification

Journal: Cell Cycle

Article Title: Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer

doi: 10.1080/15384101.2022.2159203

Figure Lengend Snippet: RILPL2 expression level in NSCLC. (A) RILPL2 expression in different tumors based on the TIMER database (Wilcox test). Red color: tumor tissue. Blue color: normal tissue. (B) Volcano plots of DEGs (include RILPL2) in tumor tissues compared with normal tissues in the TCGA cohorts (|log2fc| ≥ 1, FDR <0.05). (C) RILPL2 expression in NSCLC based on the GEPIA database (One-way ANOVA test). Red color: tumor tissue. Black color: normal tissue. (D) Western blot of RILPL2 expression. (E) Protein expression of RILPL2 in NSCLC cell lines from the CCLE database. non-small cell lung cancer; DEGs, differentially expressed genes. *p < 0.05, **p < 0.01, ***p < 0.001.

Article Snippet: Human NSCLC cell lines (A549, PC-9, NCI-H1975, NCI-H3122, NCI-H358, NCI-H2228) and human bronchial epithelial cell BEAS-2B were purchased from the American Type Culture Collection (ATCC).

Techniques: Expressing, Western Blot

Journal: Oncology Letters

Article Title: Assessment of ALK gene fusions in lung cancer using the differential expression and exon integrity methods

doi: 10.3892/ol.2016.4157

Figure Lengend Snippet: Detection of anaplastic lymphoma kinase fusion in urine from non-small cell lung cancer patients using the differential expression method.

Article Snippet: NSCLC cells and clinical samples The NCI-H3122 human NSCLC cell line (ALK fusion-positive) was provided by AstraZeneca Innovation Center (Shanghai, China).

Techniques: Quantitative Proteomics, Fluorescence In Situ Hybridization, Control